Enriched clinical annotations |
For each of the clinical annotations, we tested whether it was enriched in the set of arrays in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) module's arrays in which they appear. We also show the fraction of the module's induced (or repressed) arrays with the given annotation ('Hits (%)' column). For completeness, we also list the total number of relevant induced arrays in the module ('Module hits in category' column), total number of arrays in the compendium in which the corresponding annotation is present ('Arrays in annotation' column), and the total number of relevant arrays in the compendium ('Arrays' column). Note that the 'relevant' arrays may be different for each annotation, since it includes only arrays in which the annotation was relevant (i.e., present or not present) and excludes arrays where the value of the annotation was not known. Rows that correspond to annotations that were enriched in the induced arrays of the module have a red background, while rows corresponding to annotations enriched in the repressed arrays have a green background. For each annotation, we also list the other modules in which it was enriched. |
Clinical annotation |
Category |
P-value |
Hits |
Hits(%) |
Module hits in category |
Arrays in annotation |
Arrays |
Hematologic cancer and cell line (Stimulated PBMC) |
Stimulated PBMC |
2.9e-21 |
28 |
70 |
40 |
30 |
182 |
Macrophages (Stimulated PBMC) |
Stimulated PBMC |
2.9e-21 |
28 |
70 |
40 |
30 |
182 |
Prostate (Prostate cancer*) |
Prostate cancer* |
7.5e-18 |
73 |
11.8 |
615 |
101 |
1945 |
Cancer and cell line (Various tumors*) |
Various tumors* |
1.3e-15 |
72 |
11.7 |
615 |
105 |
1945 |
Cancer (Various tumors*) |
Various tumors* |
1.3e-15 |
72 |
11.7 |
615 |
105 |
1945 |
Epithelial cell line (NCI60) |
NCI60 |
1.5e-12 |
32 |
46.3 |
69 |
32 |
139 |
Hematologic cancer and cell line (Stimulated immune*) |
Stimulated immune* |
8.0e-10 |
25 |
9.8 |
254 |
53 |
1945 |
Hematologic samples and cell lines (Stimulated immune*) |
Stimulated immune* |
8.0e-10 |
25 |
9.8 |
254 |
53 |
1945 |
Macrophages (Stimulated immune*) |
Stimulated immune* |
8.0e-10 |
25 |
9.8 |
254 |
53 |
1945 |
Monocytes (Stimulated immune*) |
Stimulated immune* |
8.0e-10 |
25 |
9.8 |
254 |
53 |
1945 |
Liver tissue (Liver cancer*) |
Liver cancer* |
2.9e-08 |
51 |
20.0 |
254 |
187 |
1945 |
CNS tissue, cancer or cell line (Neuro tumors*) |
Neuro tumors* |
3.2e-08 |
51 |
8.2 |
615 |
85 |
1945 |
Hematologic cancer and cell line (NCI60) |
NCI60 |
8.1e-08 |
9 |
64.2 |
14 |
14 |
139 |
Hematologic samples and cell lines (NCI60) |
NCI60 |
8.1e-08 |
9 |
64.2 |
14 |
14 |
139 |
Leukemia cell line (NCI60) |
NCI60 |
8.1e-08 |
9 |
64.2 |
14 |
14 |
139 |
Liver tissue, cancer or cell line (Liver cancer*) |
Liver cancer* |
1.9e-07 |
51 |
20.0 |
254 |
197 |
1945 |
CNS cancer or cell line (Neuro tumors*) |
Neuro tumors* |
4.8e-07 |
47 |
7.6 |
615 |
81 |
1945 |
CNS tumor (Neuro tumors*) |
Neuro tumors* |
4.8e-07 |
47 |
7.6 |
615 |
81 |
1945 |
Female hormonal cancer cell line (Breast cancer) |
Breast cancer |
9.4e-07 |
9 |
52.9 |
17 |
15 |
152 |
Breast cancer cell line (Breast cancer) |
Breast cancer |
4.1e-06 |
9 |
52.9 |
17 |
17 |
152 |
Cell line (NCI60*) |
NCI60* |
4.7e-06 |
67 |
10.8 |
615 |
135 |
1945 |
Cancer and cell line (Neuro tumors*) |
Neuro tumors* |
5.1e-06 |
47 |
7.6 |
615 |
86 |
1945 |
Cancer (Neuro tumors*) |
Neuro tumors* |
5.1e-06 |
47 |
7.6 |
615 |
86 |
1945 |
Cancer and cell line (NCI60*) |
NCI60* |
5.5e-06 |
68 |
11.0 |
615 |
138 |
1945 |
B. petrussis stimulated immune cells (Stimulated PBMC) |
Stimulated PBMC |
6.8e-06 |
26 |
81.2 |
32 |
67 |
144 |
Chronic lymphocytic leukemia (B lymphoma) |
B lymphoma |
1.2e-05 |
22 |
40.7 |
54 |
46 |
245 |
Leukemia (B lymphoma) |
B lymphoma |
1.2e-05 |
22 |
40.7 |
54 |
46 |
245 |
Leukemia or leukemia cell line (B lymphoma) |
B lymphoma |
1.2e-05 |
22 |
40.7 |
54 |
46 |
245 |
Cancer and cell line (Gliomas*) |
Gliomas* |
1.6e-05 |
29 |
4.7 |
615 |
47 |
1945 |
Cancer (Gliomas*) |
Gliomas* |
1.6e-05 |
29 |
4.7 |
615 |
47 |
1945 |
CNS cancer or cell line (Gliomas*) |
Gliomas* |
1.6e-05 |
29 |
4.7 |
615 |
47 |
1945 |
CNS tissue, cancer or cell line (Gliomas*) |
Gliomas* |
1.6e-05 |
29 |
4.7 |
615 |
47 |
1945 |
CNS tumor (Gliomas*) |
Gliomas* |
1.6e-05 |
29 |
4.7 |
615 |
47 |
1945 |
Hepatitis infected liver (Liver cancer*) |
Liver cancer* |
4.3e-05 |
38 |
14.9 |
254 |
156 |
1945 |
Lung carcinoid (Lung cancer) |
Lung cancer |
5.0e-05 |
15 |
17.0 |
88 |
20 |
276 |
Classical malignant glioblastoma (Gliomas) |
Gliomas |
0.0001 |
10 |
100 |
10 |
14 |
27 |
Non-classic anaplastic oligodendroglioma (Gliomas) |
Gliomas |
0.0001 |
13 |
92.8 |
14 |
13 |
20 |
Hematologic cancer and cell line (Various tumors) |
Various tumors |
0.0002 |
5 |
100 |
5 |
31 |
154 |
Hematologic cancer (Various tumors) |
Various tumors |
0.0002 |
5 |
100 |
5 |
31 |
154 |
Primary blood mononuclear cells (Various tumors) |
Various tumors |
0.0002 |
5 |
100 |
5 |
31 |
154 |
Non-classic malignant glioblastoma (Gliomas) |
Gliomas |
0.0002 |
12 |
80 |
15 |
13 |
27 |
Hematologic samples and cell lines (Stimulated PBMC*) |
Stimulated PBMC* |
0.0003 |
40 |
15.7 |
254 |
182 |
1945 |
Monocytes (Stimulated PBMC*) |
Stimulated PBMC* |
0.0003 |
40 |
15.7 |
254 |
182 |
1945 |
Gram negative bacteria stimulated immune cells (Stimulated PBMC) |
Stimulated PBMC |
0.0003 |
26 |
81.2 |
32 |
78 |
144 |
B. petrussis A2 stimulated immune cells (Stimulated PBMC) |
Stimulated PBMC |
0.0004 |
5 |
15.6 |
32 |
5 |
144 |
B. petrussis Tox 6 stimulated immune cells (Stimulated PBMC) |
Stimulated PBMC |
0.0004 |
5 |
15.6 |
32 |
5 |
144 |